Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Long-Term Deferred Tax (2016 - 2025)

Gsk has reported Long-Term Deferred Tax over the past 10 years, most recently at $8.7 billion for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $8.7 billion for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $8.7 billion (changed 0.0% YoY), and the annual figure for FY2025 was $8.7 billion, changed 0.0%.
  • Long-Term Deferred Tax for Q4 2025 was $8.7 billion at Gsk, roughly flat from $8.7 billion in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for GLAXF hit a ceiling of $8.7 billion in Q4 2025 and a floor of $6.6 billion in Q4 2022.
  • Median Long-Term Deferred Tax over the past 5 years was $7.5 billion (2023), compared with a mean of $7.7 billion.
  • Biggest five-year swings in Long-Term Deferred Tax: increased 24.26% in 2021 and later dropped 5.65% in 2022.
  • Gsk's Long-Term Deferred Tax stood at $7.0 billion in 2021, then fell by 5.65% to $6.6 billion in 2022, then grew by 13.13% to $7.5 billion in 2023, then grew by 15.52% to $8.7 billion in 2024, then rose by 0.0% to $8.7 billion in 2025.
  • The last three reported values for Long-Term Deferred Tax were $8.7 billion (Q4 2025), $8.7 billion (Q4 2024), and $7.5 billion (Q4 2023) per Business Quant data.